Sparsentan

In a recently conducted JMP Securities’ survey, results indicated that experts support the accelerated approval pathway for Retrophin Inc (NASDAQ: RTRX)'s sparsentan and expect high usage levels in FSGS. Analyst Liisa A. Bayko reiterated a Market Outperform rating on the company, with a price...

After his former company Retrophin Inc (NASDAQ: RTRX) released positive top-line data from the Phase 2 DUET study of sparsentan, Martin Shkreli offered an olive branch to media companies wishing to speak to him on the drug he helped develop. With that, Benzinga reached out to Shkreli and...

BMO thinks Retrophin Inc (NASDAQ: RTRX) shares should touch $20 even in a worst case scenario where the upcoming Phase II DUET data for Sparsentan in FSGS delivers no benefit or unacceptable edema rates. Retrophin is BMO's top small-cap biotech pick, as it believes "shares are undervalued given...

Not often do you see sell-side firms throwing around weighty phrases such as "transformative event" for a specific company. However, JMP did just that in a note Thursday morning for Martin Shkreli's old company, Retrophin Inc (NYSE: RTRX). Within the next quarter, JMP expects to...